[Dystonia in multiple sclerosis]. / Dystonia w przebiegu stwardnienia rozsianego.

Two cases of involuntary movements of the type of segmental dystonia were observed in patients with a history of multiple sclerosis since many years. The reports on dystonic involuntary movements in multiple sclerosis are scant but, together with the present cases, they suggest that dystonia may be a sign of multiple sclerosis, although a rare one.

[Somatosensory evoked potentials (SSEP) in patients with multiple sclerosis (MS)--correlations with clinical studies]. / Badania somatosensorycznych potencjalów wywolanych (SSPW) u chorych ze stwardnieniem rozsianym (SR)--korelacje z badaniami klinicznymi.

Somatosensory evoked potentials were studied in 50 patients with clinically reliably confirmed diagnosis of multiple sclerosis in various disease stages. In a part of these patients the study was repeated after 3 years. The latency changes, amplitude changes and shape abnormalities of the obtained N9, N13 and N20 responses were evaluated. The authors discuss the observed changes of these potentials in relation to clinical findings and analyse the evolution of potential changes during the disease.

[Decaris in the treatment of multiple sclerosis]. / Ocena preparatu Decaris w leczeniu stwardnienia rozsianego.

Decaris was given for 6 months to 57 patients with clinically reliably diagnosed multiple sclerosis. For evaluating the physical fitness of the patients the 10-point scoring system of Kurtzke was used. The drug was given intermittently to 2 groups of patients in a 14-day cycle of 3 tablets daily for 3 days: and in a 7-day cycle of 3 tablets for 3 days. Each tablet contained 50 mg of the drug. The effects of the drug were evaluated on the course of the disease, dynamics of neurological status changes, and side effects. The progression of the disease process was slowed down, the function of the pyramidal system and labyrinthine-cerebellar systems became normal or improved. Sphincter control was better. The best results were obtained in patients with remitting form of the disease treated in the 14-day cycle.